Does Medi-Cal Cover Wegovy? 2026 Rules and 5 Coverage Paths

Some links elsewhere on The RX Index may be sponsored. That never changes the coverage answer. The lowest-cost paid path on this page is manufacturer-direct, and we still put it first.

Does Medi-Cal cover Wegovy? No — not for adults age 21 and over who are taking it for weight loss. That coverage ended January 1, 2026. Five paths can still lead to coverage: noncirrhotic MASH, established cardiovascular disease, an EPSDT review for members under 21, a temporary continuation rule for some under-21 members, and a narrow rule for adult prior authorizations submitted from January 1 through March 31, 2026.

Here's the part almost nobody has caught.

On April 1, 2026, California made one Wegovy path much easier. If you have noncirrhotic MASH, Wegovy injection no longer needs prior approval. Your prescriber must send an accurate diagnosis code with the prescription. A lot of older pages still describe only the January cutoff.

So the honest answer isn't "no." It's "no, unless one of five things is true." And one of those five has a deadline that hits October 1, 2026.

Let's find out which one is you.

This page is for you if:

• You have Medi-Cal, and your Wegovy was denied, stopped, or is about to be
• You're trying to figure out a prior authorization, an appeal, or a pharmacy rejection code
• Someone in your family under 21 takes Wegovy
• You want to know what it actually costs if Medi-Cal won't pay

Read something else if:

• You have Covered California, an employer plan, CalPERS, or Medicare only — the rules are completely different
• Your question is really about Ozempic for type 2 diabetes — that's still covered for that use with the required diagnosis code; see the drug table below
• You're comparing Wegovy to other medications rather than checking Medi-Cal coverage

Your answer in one screen

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Not sure which row is you? Start with the five coverage paths. Your age, the real reason Wegovy was prescribed, and your claim history decide the answer.

What we actually verified

On August 7, 2026, we opened and read:

• The Medi-Cal Rx Contract Drugs List dated August 1, 2026
• Four Medi-Cal Rx pharmacy alerts and member notices covering the January cutoff, the April MASH change, and the April continuation rules
• The Medi-Cal Rx member FAQ, Version 5.0, dated April 6, 2026
• The live Medi-Cal Rx Diagnosis Crosswalk
• State Plan Amendment 25-0029 and the CMS letter approving it, dated March 12, 2026
• The current FDA prescribing information for Wegovy
• Novo Nordisk's pricing, self-pay terms, list price, and NovoCare Pharmacy details
• Current Ro and Sesame eligibility terms
• The current Medi-Cal Rx State Fair Hearing form and California hearing instructions

Every rule and price below traces back to one of those. All linked at the bottom.

What we did not verify: your diagnosis, whether your prior authorization will be approved, whether your hearing will succeed, or what your pharmacy has in stock. Nobody online can tell you that. What we can do is show you exactly what California's own paperwork says.

Why the answer depends on three facts — and how to skip the guessing

You do not need a provider quiz to solve the coverage question. You need three facts:

1. Your age: under 21, or 21 and older
2. The reason on the prescription: weight loss, MASH, cardiovascular disease, or something else
3. Your claim history: a paid claim in 2026, an approved PA, or a denial notice

Match those three facts to the table above. Do not pick the diagnosis that sounds easiest. Use the diagnosis that is actually in your medical record.

One note before you go further: compounded semaglutide is not Wegovy. It is not an FDA-approved product. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. Everything on this page is about FDA-approved Wegovy unless a sentence clearly says otherwise.

Does Medi-Cal cover Wegovy in 2026?

Answer: Medi-Cal does not cover Wegovy for weight loss for members age 21 and older. That rule took effect January 1, 2026 under California's approved Medicaid state plan. Coverage still exists for noncirrhotic MASH, certain cardiovascular use, members under 21, and two narrow continuation situations.

What actually changed on January 1

Three drugs came off California's covered path for weight loss: Wegovy, Zepbound, and Saxenda.

Seven others stayed covered for type 2 diabetes — Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, and Trulicity — when the required diabetes diagnosis code is on the claim.

Weight-loss prior authorizations that existed before January 1 expired December 31, 2025. In April, the state created two narrow continuation rules. Those rules do not restore a broad grandfather policy.

Here's the thing most people get wrong about their own coverage

For a standard outpatient prescription billed on a pharmacy claim, your Medi-Cal health plan did not set this Wegovy rule. Your county did not set it.

California runs that pharmacy benefit through a statewide program called Medi-Cal Rx. Whether your card says L.A. Care, Kaiser, Health Net, IEHP, or Partnership, the standard outpatient pharmacy claim is handled under the same state policy.

That matters, because the best first call for a pharmacy rejection or prior-authorization status is Medi-Cal Rx, not a plan formulary department. Your health plan can still help with care coordination, but it does not write this statewide pharmacy rule.

There are narrow system exceptions. Medi-Cal Rx does not apply to PACE plans, SCAN, or MRMIP, and drugs billed on a medical or institutional claim can follow a different route. This page is about the normal outpatient prescription filled by a pharmacy.

What "non-benefit" actually means

Here's a detail from the state's own drug list that tells you a lot.

The Medi-Cal Rx Contract Drugs List runs hundreds of pages. In it, there are exactly two headings that name a drug group as a non-benefit. The first is erectile dysfunction drugs, which California stopped covering in 2006. The second is "GLP-1 Drugs for Weight Loss: Non-Benefit."

That's a different thing from a drug being "non-preferred" or needing extra paperwork. A non-benefit isn't a hurdle you clear with a better weight-loss prior authorization. The state isn't buying it for that purpose for adults 21 and older.

A common mistake is a doctor's office resubmitting the same adult weight-loss request over and over. It won't work if nothing about the claim is different. It's not a paperwork problem.

But — and this is the whole point of this page — the exclusion is written for GLP-1 drugs used for weight loss or weight-loss-related indications. If a different covered condition is truly present, diagnosed, and documented, the coverage rule can be different.

The five coverage paths: which one applies to you?

Answer: Five specific situations can still lead to Wegovy coverage through Medi-Cal in 2026 — noncirrhotic MASH, established cardiovascular disease, members under 21 through EPSDT review, a temporary override for some under-21 members already in treatment, and approved adult PAs based on requests submitted from January 1 through March 31, 2026. Your age, diagnosis, and claim history decide which one applies.

This table combines the August Contract Drugs List, two April Medi-Cal Rx alerts, the member FAQ, the current diagnosis crosswalk, the FDA label, and the state hearing form in one place.

Check your own path in 60 seconds

Write down three answers:

• Are you under 21?
• Why did the prescriber order Wegovy: weight loss, MASH, cardiovascular disease, or another reason?
• Do you have a paid 2026 claim, an approved PA tied to a January–March 2026 request, or a Notice of Action?

Now start with the first row above that matches all three facts. Do not stack a diagnosis you do not have onto the claim. If no covered row fits, go to the cash-pay section or other Medi-Cal weight-treatment options.

Does Medi-Cal cover Wegovy for weight loss?

Answer: No. For members age 21 and older, Medi-Cal Rx treats GLP-1 drugs used for weight loss or weight-loss-related reasons as a non-covered benefit as of January 1, 2026. Body mass index does not change this. There is no adult weight-loss prior authorization pathway under current policy.

Does a BMI of 30 or 35 qualify me?

No.

You will find pages telling you that Medi-Cal covers Wegovy at a BMI of 30, or 27 with a related condition, if you meet certain criteria. Those pages are describing old Medi-Cal rules or another insurance program.

We're not saying that to score a point. We're saying it because if you walk into your doctor's office asking them to submit a BMI-based adult Medi-Cal request, you can lose weeks waiting for a denial that the current policy already predicts.

Can my doctor just try again?

Only if something is actually different.

A new prior authorization makes sense when:

• A genuinely covered condition applies and hasn't been submitted yet
• The first request was missing information the state asked for
• Your claim had a code, product, timing, or pharmacy error in it
• You are under 21 and need an EPSDT medical-necessity review

A new prior authorization does not make sense when the reason is still adult weight loss and nothing else has changed.

And here's a hard one that we think you deserve to know.

California's October 2025 notice said continuation-of-therapy requests would be denied, and an earlier notice said continuation alone would not justify approval. The state later created two narrow April exceptions: the under-21 temporary override and the adult January–March request window.

Outside those two exceptions, "It's been working for me for two years" is still not enough by itself.

We hate that. But you're better off knowing it before you spend a month on it. What can change the answer is a covered diagnosis that is truly in your chart, an approved under-21 EPSDT request, or one of the two narrow continuation rules.

Does Medi-Cal cover Wegovy for MASH?

Answer: Yes. Medi-Cal Rx covers Wegovy injection for noncirrhotic MASH, and since April 1, 2026, that use has not required prior authorization. The pharmacy claim still needs an accurate diagnosis code accepted by the current Medi-Cal Rx crosswalk. The Wegovy tablet is not the MASH product in the FDA label or the Medi-Cal Rx MASH listing.

This is the biggest change since January, and it is the one most older articles miss.

What MASH is, in plain words

MASH stands for metabolic dysfunction-associated steatohepatitis. It used to be called NASH.

It is a liver disease. Fat builds up in the liver, the liver becomes inflamed, and scar tissue forms. It is tied to metabolic disease and extra weight, but it is not the same thing as being overweight, and it is not the same thing as a note that simply says fatty liver.

The FDA-approved MASH use is for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, stages F2 to F3. FDA granted this indication under accelerated approval based on improvement in MASH and fibrosis; continued approval may depend on confirmation of clinical benefit. That is a real clinical diagnosis. A pharmacy code is not a shortcut around it.

If you have abnormal liver tests, liver imaging, or a history of fatty liver and have never had it worked up, asking your clinician whether you need an evaluation is reasonable. Asking someone to put a diagnosis in your chart that you do not have is not.

The line we are going to draw clearly

Never ask a clinician to record a condition you do not have.

Medi-Cal Rx tells prescribers to put the diagnosis code in the medical record for auditing. A code used only to make a claim pay can create serious problems for the member and the prescriber.

Asking to be evaluated for a condition is completely different. Getting checked and learning that you have MASH is not the same as pretending you do.

Which code goes on the claim — and the official source conflict

This is where the state documents do not match.

The April 6, 2026 Medi-Cal Rx alert names K76.0 and/or K75.8. The current Medi-Cal Rx diagnosis crosswalk checked on August 7, 2026 lists K75.81 and K76.0 for Wegovy, effective April 1, 2026.

K75.8 and K75.81 are not the same entry.

Source-version note: The April alert and the live crosswalk use different code sets. The pharmacy should check the current Medi-Cal Rx diagnosis crosswalk when the claim is submitted. The prescriber should use only the code that accurately matches the medical record. If a valid MASH claim rejects, ask whether the pharmacy used the current crosswalk rather than an older alert.

We are publishing the conflict instead of picking one document and hiding the other, because the live claim system can change after an alert is issued.

One more thing matters: the crosswalk is a payment edit, not a diagnosis guide. A code appearing in the crosswalk does not, by itself, prove that someone has the FDA-labeled MASH condition.

The quantity rule that can cause a separate rejection

The August 2026 Contract Drugs List covers the Wegovy injectable listing at one carton of four single-dose pens per dispensing, once every 28 days, with labeler code 00169.

That means a claim can have the right diagnosis and still reject because of the product, quantity, NDC, or refill timing. A refill-too-soon message is not the same thing as a MASH coverage denial.

Why a real MASH claim might still reject

Ask the pharmacy to check, in this order:

1. Was any diagnosis code sent with the claim?
2. Does the code match the current Medi-Cal Rx crosswalk?
3. Does the code accurately match the diagnosis in the medical record?
4. Is the prescription for Wegovy injection, not the tablet?
5. Is it the covered product and labeler?
6. Does the quantity and refill date fit the 28-day limit?
7. Is there another claim edit or old authorization record affecting the fill?

That list turns “Medi-Cal said no” into a question the pharmacy can actually answer.

Does Medi-Cal cover Wegovy for heart disease?

Answer: Possibly. Medi-Cal Rx reviews prior authorization requests for Wegovy used for cardiovascular disease case by case. The FDA-approved cardiovascular use applies to adults with established cardiovascular disease who also have overweight or obesity. A risk factor alone is not the same thing.

What “established cardiovascular disease” means

The FDA approved Wegovy to reduce the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults who already have cardiovascular disease and also have overweight or obesity.

Prior heart attack, prior stroke, and peripheral artery disease are the clearest examples in the FDA evidence. High cholesterol, high blood pressure, a family history, or being told that you are “at risk” do not by themselves equal established cardiovascular disease.

If you have a documented cardiovascular diagnosis, this door is worth working. If you only have risk factors, do not build your whole plan around an approval that the published criteria do not promise.

Exactly what the prior authorization must contain

California lists six core items in its Contract Drugs List:

1. The diagnosis or diagnoses
2. The quantity and days supply requested
3. Other products already tried, and why they did not meet the member’s needs
4. Contraindications and allergies
5. Chart notes and lab reports
6. Supporting literature, compendia, or treatment guidelines when the requested use is off-label

Print that list or copy it into the message to the person filing the request. Do not let the submission say only “cardiovascular risk” if the chart contains a more specific established diagnosis. Do not leave the prior-treatment section blank when there is real history to report.

Is approval guaranteed?

No. “Case by case” means Medi-Cal Rx reviews the member’s own record and medical-necessity support. Meeting the FDA label is important, but it does not create an automatic paid claim.

The productive next step is not another general phone call. It is one complete request with the diagnosis, records, quantity, prior treatment, and supporting notes in the same submission.

Does Medi-Cal cover Wegovy for someone under 21?

Answer: It may, after approval. Federal EPSDT rules require Medicaid to review medically necessary treatment for members under 21 instead of applying the adult weight-loss exclusion as a blanket rule. Medi-Cal Rx uses prior authorization for that review. A temporary override is also paying some qualifying Wegovy claims through September 30, 2026.

This is the most time-sensitive section on the page. If it applies to your family, read all of it.

What EPSDT is

EPSDT stands for Early and Periodic Screening, Diagnostic, and Treatment. It is a federal Medicaid protection for people under 21.

In plain words: California still gets to decide whether the requested treatment is medically necessary, but it has to review the child or young adult’s own case. It cannot use the adult exclusion as the whole answer.

The Medi-Cal Rx member FAQ says this pathway applies whether or not the member is enrolled in California Children’s Services.

The temporary rule running now

Medi-Cal Rx put a temporary continuation override into effect on April 27, 2026. A qualifying under-21 Wegovy claim can pay when both of these are true:

• The new claim has a date of service on or after April 1, 2026, and
• The member has a paid Wegovy claim dated January 1, 2026 or later in claim history

If an earlier claim rejected and both facts are now true, the pharmacy can try the claim again. All other claim edits still apply.

What happens after September 30, 2026

The temporary override ends September 30, 2026.

Starting October 1, 2026, an affected claim needs one of these or it can reject:

• An active, approved prior authorization, or
• An appropriate diagnosis code accepted for the MASH restriction

Medi-Cal Rx told providers to submit new prior authorization requests before October 1. Do not wait for the override to end and then start the paperwork.

What the under-21 request needs

Use the same six-item list from the cardiovascular section:

1. Diagnosis
2. Quantity and days supply
3. Other treatment tried and why it did not meet the member’s needs
4. Contraindications and allergies
5. Chart notes and lab reports
6. Supporting literature or guidelines when the use is off-label

Include the records that actually show medical need. That can include growth history, prior treatment, relevant lab work, and current clinical notes when they apply. More pages are not automatically better. The goal is a complete, specific record.

I was already taking Wegovy. Am I grandfathered in?

Answer: There is no broad grandfather rule. Weight-loss prior authorizations that existed before 2026 expired December 31, 2025. Two narrow continuation rules now exist: the temporary under-21 override and approved adult prior authorizations tied to requests submitted from January 1 through March 31, 2026.

This answer changed after the January cutoff, which is why older pages and letters can sound final even when a narrow April update now applies.

The adult exception almost nobody knows about

If you are 21 or older and have an approved Wegovy prior authorization based on a request submitted from January 1 through March 31, 2026, Medi-Cal Rx says it will honor that approval through the end of its authorization period.

The date that matters is when the request was submitted. Do not reduce the rule to “approved during those three months.”

If a claim rejects and you believe the approved PA came from a request submitted in that window, ask Medi-Cal Rx to review the April 28, 2026 temporary continuation update.

Your timeline, at a glance

What does the rejection code on my Wegovy claim mean?

Answer: Reject Code 80 means the diagnosis code on the claim did not meet the drug’s coverage rule. Reject Code 70 means the product or service is not covered as submitted. Since April 1, 2026, Wegovy claims commonly use Code 80 because Wegovy has a diagnosis restriction. Adult weight-loss claims for Zepbound and Saxenda generally sit in Code 70 territory, with separate exceptions such as Zepbound for obstructive sleep apnea and EPSDT review for members under 21.

This is useful at the pharmacy counter because the two codes call for different questions.

Why Wegovy moved from one code to the other

At the start of 2026, the Wegovy weight-loss change was being processed as a product-not-covered rejection. Effective April 1, the state added a Wegovy diagnosis restriction for noncirrhotic MASH. That changed the claim logic: Wegovy can be covered for a narrow reason, so a claim without an accepted reason can return Code 80.

For an adult weight-loss-only claim, Code 70 is a closed benefit path. Code 80 says there may be a code, PA, product, or continuation record to check. Knowing which one you have can save a month of calls aimed at the wrong problem.

What to say when you call

“My Wegovy claim returned Reject Code 80. Can you tell me which diagnosis code was submitted, whether it was checked against the current Medi-Cal Rx crosswalk, and whether an approved prior authorization or continuation record appeared in the system?”

That sentence gives the pharmacy a concrete job instead of asking it to solve your whole coverage problem at the counter.

What if Medi-Cal denied my Wegovy?

Answer: A Medi-Cal member who receives a Notice of Action denying a GLP-1 drug has a right to request a State Hearing. The usual hearing deadline is 90 days from the notice. Continuing the medication while the hearing is pending — called aid paid pending — has a faster and narrower rule: it applies to a service the member is already receiving, and the request generally must be made within 10 days of the date on the notice or before the stated service-end date, whichever is later.

First, figure out what kind of “no” you got

There is a big difference between these three:

• A pharmacy claim rejection — a billing code came back at the counter. It may be fixable without a hearing.
• A denied prior authorization — Medi-Cal Rx reviewed the request and denied it. The Notice of Action explains hearing rights.
• A correctly applied benefit exclusion — the drug is excluded for the requested adult weight-loss use. You can still use the hearing process described in the notice, but repeating the same facts does not create a covered benefit.

If you are 21 or older, the prescription is for weight loss only, and the exclusion was applied correctly, first check whether there is a factual error or one of the five coverage paths. Do not let someone sell you certainty that an appeal can erase the exclusion.

The 90-day rule

You generally have 90 days from the date of the Notice of Action to request a State Hearing. Follow the deadline and instructions printed on your own notice if they differ.

You can request a hearing through the California Department of Social Services online, by phone, mail, or fax. The official hearing request page is cdss.ca.gov/hearing-requests.

The aid-paid-pending rule most people miss

Aid paid pending is not a general promise that every denied prescription keeps paying during an appeal.

It is for continuation of a service you were already receiving. The state hearing form says to ask within 10 days of the date on the notice or before the date the service is supposed to stop, whichever is later. Use the exact words:

“I am requesting aid paid pending.”

If the request qualifies, the current service may continue while the hearing is pending, subject to the limits in the notice and the existing authorization. Read the notice as soon as it arrives. Ten days can pass before a normal follow-up appointment happens.

When a hearing is less likely to change the result

Be honest with yourself about the record. A hearing is less likely to change the outcome when all of these are true:

• The use is adult weight loss only
• The state applied the exclusion correctly
• No claim or diagnosis error exists
• No covered indication applies
• The member is not protected by an under-21 pathway
• No approved adult PA from the January–March request window exists

That is not a reason to ignore your formal rights. It is a reason to work the next useful path at the same time instead of waiting with no backup plan.

Who to call

Medi-Cal Rx Customer Service: 1-800-977-2273. It is available 24 hours a day, 7 days a week, 365 days a year. Ask about the claim, PA status, rejection code, or continuation record.

California Department of Social Services State Hearings: 1-800-743-8525. Use this for hearing-process questions and follow the contact instructions on your Notice of Action.

Does L.A. Care, Kaiser, or my county change the answer?

Answer: Usually no for a standard outpatient prescription filled at a pharmacy. Medi-Cal Rx uses one statewide drug list and one statewide set of pharmacy claim rules. Your managed care plan can still help coordinate care, but it does not create a separate adult Wegovy weight-loss formulary.

We are addressing this because old plan-by-plan advice can send people to the wrong office.

Why the confusion exists

California moved most Medi-Cal outpatient pharmacy benefits into Medi-Cal Rx. Before that change, managed care plans handled more of the pharmacy benefit themselves. A lot of pages still describe the old setup.

There is a second source of confusion: the same organization can sell different kinds of insurance. L.A. Care Medi-Cal is not the same product as L.A. Care Covered. Kaiser Medi-Cal coverage is not the same as Kaiser employer or individual commercial coverage.

What this means for you

• For a pharmacy rejection or Medi-Cal Rx PA, start with the pharmacy, prescriber, or Medi-Cal Rx.
• Your health plan can still help with care coordination, appointments, referrals, and finding a clinician.
• Do not use a commercial-plan formulary to predict a Medi-Cal Rx claim.
• Check what coverage is actually on your card before using this page.

There are narrow exceptions. Medi-Cal Rx does not apply the same way to PACE, SCAN, or MRMIP, and a drug billed as part of a medical or institutional service can follow a different claim route. This page covers the normal outpatient pharmacy benefit.

What if I have both Medi-Cal and Medicare?

If you have Medicare drug coverage, your prescription usually runs through Medicare Part D before Medi-Cal Rx. That changes the answer.

Medicare launched Medicare GLP-1 Bridge on July 1, 2026. Eligible Medicare drug-plan members can get certain covered GLP-1 weight-loss drugs, including Wegovy injection or tablets, for $50 for a monthly supply after the program approves them. It is not automatic, and not every person with Medicare qualifies.

Do not assume the Medi-Cal-only answer is yours. Check Medicare first or use our separate guide: Does Medicare cover Wegovy for weight loss?

Can I pay for Wegovy myself while I am on Medi-Cal?

Answer: Yes. Medi-Cal says members may pay out of pocket for a GLP-1 drug. Medi-Cal Rx will not reimburse an adult weight-loss purchase. Novo Nordisk also says people enrolled in government-funded health programs may use its Wegovy self-pay price outside insurance when they meet the program terms and have a valid prescription.

Now for the number that changes the decision.

A lot of people hear “not covered” and think the only other number is the widely quoted $1,349.02 list price for a Wegovy injection package. It is not.

The sentence that opens the cash door

Novo Nordisk’s current terms say patients enrolled in government, state, or federally funded medical or prescription programs can pay the self-pay price. The purchase stays outside insurance and cannot be submitted for reimbursement.

That creates two different programs with opposite eligibility rules:

• The commercial savings card can reduce an eligible commercially insured patient’s cost to as little as $25. Government program beneficiaries are excluded.
• The manufacturer self-pay offer works outside insurance. Government-insured patients may use it when they meet the self-pay terms.

Do not hand a pharmacy the commercial savings card and expect it to work with Medi-Cal. Ask for the self-pay program.

What Wegovy costs through the manufacturer self-pay program

Prices verified August 7, 2026. Novo Nordisk can change or end these offers, so check the live price before the prescription is filled.

At the standard pen price, the gap between list price and manufacturer self-pay is about $1,000 per package.

Two limits matter: Medi-Cal will not repay you for the purchase, and the money does not count toward an insurance deductible or out-of-pocket limit. The manufacturer program also requires a valid prescription for an FDA-approved Wegovy use.

The lowest-cost place to start — and we do not make a dime from it

Here is the part where we tell you to start with the route that earns us nothing.

Use the clinician you already have before paying a second company for a visit. Your Medi-Cal clinic may already give you access to the prescriber you need, although normal eligibility, share-of-cost, and appointment rules still apply.

The cleanest cash path is:

1. Ask your current clinician whether Wegovy is medically appropriate for you.
2. If they prescribe it, ask them to send the prescription to NovoCare Pharmacy.
3. Pay the manufacturer self-pay price outside Medi-Cal.
4. Confirm the exact dose price before the order ships.

NovoCare Pharmacy lists free standard shipping and does not require a separate monthly telehealth membership.

Here are the prescriber details published by NovoCare:

NovoCare Pharmacy 2400 Sand Lake Rd, Ste. 200B Orlando, FL 32809 NPI: 1710671854 NCPDP: 5758074 Phone: 1-833-949-5527 Fax: 1-833-947-0246

You can also start at the manufacturer’s official NovoCare Wegovy pharmacy page.

No Medi-Cal coverage paperwork. No reimbursement. No promise that your clinician will prescribe it. Just the shortest legitimate cash route when the covered paths do not fit.

When a telehealth visit makes sense — and two programs that will not work for you

Answer: A private cash-pay visit can make sense when you cannot reach a prescriber through your current care. But a Medi-Cal member should not assume every cash telehealth site will accept them. Ro currently says Medicaid patients are not eligible for treatment, and Sesame’s terms require users to certify that they are not Medicare, Medicaid, or TRICARE beneficiaries.

Ro is not an option while you have Medicaid

Ro’s current weight-loss insurance page says patients with Medicaid and some other government-funded plans are not eligible for treatment on Ro.

We mention Ro on other pages because it can be a useful fit for other insurance situations. We are not sending a Medi-Cal member there. It would waste your time.

Sesame is not a cash workaround for a Medi-Cal member

The original draft treated Sesame as a cash-pay backup. Its current terms do not support that recommendation.

Sesame says it does not accept Medicare, Medicaid, or other third-party insurance. More importantly, its terms require the user to certify that they are not a federal health care program beneficiary, including Medicaid.

That means a Medi-Cal member should not sign up by treating “cash-pay” as permission to ignore current enrollment. Paying cash and being eligible to use a platform are two different questions.

When paying for a separate visit may still be worth it

A private visit may solve the real bottleneck when:

• Your current clinician will not discuss or prescribe an uncovered cash medication
• The next available visit is too far away
• You have moved or do not have an assigned clinician you can reach
• You need a second clinical opinion and understand it may not end with a prescription

Before paying, ask the service in writing:

1. Do you accept a patient who is currently enrolled in Medicaid if the visit and medicine are fully self-pay?
2. Is there a one-time visit option, or does a membership renew?
3. Can the clinician send an appropriate prescription to NovoCare Pharmacy?
4. What is the full visit price before labs or follow-up?
5. Will I still owe the visit fee if the clinician decides Wegovy is not appropriate?

Do not pay until the first answer is a clear yes.

Provider-stated versus verified on August 7, 2026

That is the whole decision. The medicine can have a cash price while a particular telehealth company still says no to the patient.

What else will Medi-Cal cover to help with weight?

Answer: California did not erase every weight-management drug or service from Medicaid. Its approved state plan keeps select non-GLP-1 agents used for weight loss as possible benefits when medically necessary, while carving out GLP-1 drugs used for adult weight loss. A drug that is not listed on the Contract Drugs List may still require prior authorization and individual review.

This is the finding that changes what you should ask at the next appointment.

California excluded one drug class, not every weight-treatment path

In State Plan Amendment 25-0029, California kept select agents used for anorexia, weight loss, or weight gain as potential benefits subject to medical necessity. Then it added a separate exclusion for GLP-1 agonists used for weight loss.

That difference matters.

It does not mean every non-GLP-1 weight-loss drug is automatically covered. It means the state did not make the whole category a non-benefit. The current Contract Drugs List also says unlisted prescription drugs may be covered after authorization by a Medi-Cal consultant.

What to ask instead of resubmitting Wegovy

Bring this question to the appointment:

“Medi-Cal excludes GLP-1 drugs for adult weight loss, but California still allows some other weight-treatment drugs when medically necessary. Is there a non-GLP-1 option that fits my health history, and would you submit the authorization if it is needed?”

That is a better question than asking the office to send the same excluded Wegovy request again.

The answer still depends on your medical history, other medicines, pregnancy status, blood pressure, heart history, and other safety factors. This page cannot choose the drug for you. It can keep you from asking the wrong coverage question.

Does Medi-Cal cover Ozempic, Zepbound, or Saxenda instead?

Answer: Medi-Cal Rx still covers several GLP-1 drugs for type 2 diabetes when the claim carries an accepted diabetes diagnosis and meets the product restrictions. Zepbound and Saxenda are not adult weight-loss substitutes under Medi-Cal. Zepbound has a separate case-by-case prior authorization path for obstructive sleep apnea. Wegovy has the MASH, cardiovascular, and under-21 paths explained above.

One July 2026 change worth knowing

Medi-Cal Rx added Ozempic tablets in 1.5 mg, 4 mg, and 9 mg strengths to the Contract Drugs List effective July 1, 2026, with diagnosis and product restrictions.

If you have type 2 diabetes and the tablet form matters to you, ask the prescriber to check the current listing. If you do not have type 2 diabetes, the tablet is not a weight-loss workaround.

The switch that is not really a switch

Ozempic and Wegovy contain semaglutide, but they are different FDA-approved products with different labels, doses, and claim rules.

Medi-Cal Rx pays based on the product, covered use, diagnosis edit, and any required authorization. A prescription for Ozempic without a covered diagnosis does not become payable because Wegovy was denied.

If you have type 2 diabetes, this is a real discussion to have with your clinician. If you do not, it is the same coverage wall with a different brand name painted on it.

And on compounded semaglutide

Compounded semaglutide is not Wegovy and is not an FDA-approved product. FDA does not review a compounded drug for safety, effectiveness, or quality before it is marketed.

Medi-Cal has separate general rules for compounded prescriptions, but those rules do not create a standard adult compounded-semaglutide weight-loss benefit or turn a compounded product into covered Wegovy. We are not routing a Medi-Cal member to a compounded product on this page.

For the separate safety and legal picture, see Is compounded GLP-1 still available?

What to do this week

Answer: Pick the action that matches the reason for the claim. A diagnosis-code correction, prior authorization, hearing, and cash purchase solve four different problems. Starting all four at once usually creates more confusion, not more coverage.

If you are 21 or older and the prescription is for weight loss only: Ask whether a different covered condition truly applies. If not, stop repeating the same PA and compare the manufacturer cash route with other covered treatment.

If you have diagnosed noncirrhotic MASH: Confirm that the prescription is for Wegovy injection. Ask which code is being sent, whether it matches the current crosswalk and medical record, and whether the fill fits the 28-day quantity rule.

If you have established cardiovascular disease: Gather the diagnosis, chart notes, relevant labs, quantity, prior treatment history, contraindications, and allergies. Have the prescriber submit all six state-required items together.

If you or your child is under 21: Have a complete EPSDT prior authorization submitted before the temporary override ends on September 30, 2026. Do not use the temporary paid claim as proof that no PA will be needed in October.

If you have an approved adult PA tied to a request submitted from January 1 through March 31, 2026: Save the approval notice. If the pharmacy rejects the claim, ask Medi-Cal Rx to check the April 28 continuation rule.

If you received a Notice of Action: Read the date and service-end date now. The normal hearing window is 90 days. Aid paid pending has the faster continuation rule described in the denial section.

If none of the covered paths fits: Ask your current clinician about other covered treatment first. Then compare the direct manufacturer self-pay price before paying a telehealth membership or a retail list price.

Questions California members are asking

We looked for the words real Medi-Cal members use when the letter arrives. One California member wrote in a Wegovy support forum in November 2025: “Medical won't cover my Wegovy beginning January.” The next questions were: “What do we do then?” and “I can't afford out-of-pocket cost — what are my options?”

That is the whole page in two sentences. It is why the order here is coverage first, deadline second, cash last.

Why we do not use testimonials as coverage proof: Someone else’s success cannot tell you whether your claim will pay. Age, diagnosis, product form, PA history, and the code on the claim decide that. We use member language to understand the problem, not to prove eligibility.

Frequently asked questions

Does Medi-Cal cover Wegovy for weight loss?

No, not for members age 21 and older. GLP-1 drugs used for weight loss or weight-loss-related indications became a non-covered benefit on January 1, 2026. Members under 21 have a separate EPSDT review path.

Does a BMI over 30 or 35 qualify me?

No. BMI does not override the adult Medi-Cal exclusion. The FDA label’s BMI criteria do not create a current Medi-Cal adult weight-loss PA path.

Does Medi-Cal cover Wegovy for MASH?

Yes. Since April 1, 2026, Wegovy injection for noncirrhotic MASH has used a diagnosis-code restriction instead of prior authorization. The FDA-labeled MASH use is for adults with moderate-to-advanced fibrosis, stages F2 to F3.

Does Medi-Cal cover the Wegovy tablet for MASH?

No MASH path is shown for the tablet. The FDA MASH indication and the Medi-Cal Rx MASH listing are for Wegovy injection.

What diagnosis code does my clinician need for MASH?

The code must be accurate for your medical record. The April state alert lists K76.0 and/or K75.8. The current diagnosis crosswalk checked August 7, 2026 lists K75.81 and K76.0. Ask the pharmacy to check the live crosswalk when the claim is submitted.

Does Medi-Cal cover Wegovy for heart disease?

Possibly, after case-by-case prior authorization review. The FDA cardiovascular use is for adults with established cardiovascular disease plus overweight or obesity, not for risk factors alone.

Does Medi-Cal cover Wegovy for a child or teenager?

It may after an EPSDT prior authorization is approved. The state must review medical necessity for members under 21. Approval is not automatic, and the rule applies whether or not the member is enrolled in California Children’s Services.

What happens September 30, 2026?

The temporary under-21 continuation override ends. Starting October 1, affected claims need an active approved PA or an accepted MASH diagnosis code.

I have taken Wegovy for years. Am I grandfathered in?

Not under a broad rule. Two narrow continuation paths exist: the under-21 temporary override and approved adult PAs tied to requests submitted from January 1 through March 31, 2026.

Does L.A. Care, Kaiser, or my county have a different Wegovy pharmacy rule?

Usually no for the standard outpatient pharmacy benefit. Medi-Cal Rx applies statewide. PACE, SCAN, MRMIP, and medical or institutional claims can follow different routes.

Can I appeal a denial?

A Notice of Action gives you State Hearing rights. The usual request period is 90 days. Aid paid pending applies to continuation of a service already being received and generally requires a request within 10 days of the date on the notice or before the stated service-end date, whichever is later.

Can I pay cash while I have Medi-Cal?

Yes. Medi-Cal permits out-of-pocket payment and will not reimburse an adult weight-loss purchase. Novo Nordisk’s self-pay terms allow government-insured patients to pay outside insurance when they meet the terms.

Can I use the $25 Wegovy savings card?

Not as a Medi-Cal beneficiary. The commercial savings card excludes government program beneficiaries. The manufacturer self-pay program is different and currently allows eligible government-insured patients to pay outside insurance.

What does Reject Code 80 mean?

The claim’s diagnosis code did not meet the drug’s coverage criteria. Check whether a code was sent, whether it matches the current crosswalk and medical record, and whether a PA or continuation record should apply.

What does Reject Code 70 mean?

The product or service is not covered as submitted. For an adult weight-loss-only Zepbound or Saxenda claim, that generally means there is no counter-level fix. Separate OSA, under-21, or other valid paths must be handled under their own rules.

Does Ro accept Medi-Cal members for its weight-loss program?

No. Ro currently states that Medicaid patients are not eligible for treatment on Ro.

Can I use Sesame as a cash-pay Medi-Cal workaround?

No under Sesame’s current terms. Sesame says it does not accept Medicaid and requires users to certify that they are not Medicaid beneficiaries.

What if I have both Medicare and Medi-Cal?

Check Medicare Part D first. Some eligible Part D members can use Medicare GLP-1 Bridge for a $50 monthly supply after approval. Do not use the Medi-Cal-only answer without checking the Medicare route.

Still not sure which GLP-1 path fits after checking Medi-Cal?

Start with the five coverage paths on this page. They are the five current Medi-Cal payment paths this review could verify for Wegovy.

After that, The RX Index Find My GLP-1 Path tool can help you compare the next treatment-access options. It takes about two minutes and does not require signup. It does not diagnose a condition, submit a Medi-Cal PA, or replace the state’s coverage decision.

How we verified this page

We used primary sources for every coverage, code, medical-label, hearing, and price claim. State policy came from Medi-Cal Rx, DHCS, CMS, and CDSS. Medical indications came from the current FDA Wegovy prescribing information. Prices and program terms came from Novo Nordisk. Provider eligibility came from each provider’s own current policy or terms.

We compared the April MASH alert with the current diagnosis crosswalk instead of assuming they matched. They do not. We also checked the adult continuation rule against the April 28 alert and the aid-paid-pending rule against the actual State Fair Hearing form.

Forum posts were used only to understand the words members use. They were not used as evidence for coverage, safety, price, or eligibility.

What this page cannot tell you: whether you have a diagnosis, whether a PA or hearing will succeed, whether a clinician will prescribe Wegovy, or whether a pharmacy has the product in stock.

Verification record

Update log

• August 7, 2026 — Published after checking the August 1 Contract Drugs List, April Medi-Cal Rx alerts, current diagnosis crosswalk, member FAQ, State Plan Amendment 25-0029, State Fair Hearing form, FDA label, NovoCare prices and terms, Medicare GLP-1 Bridge, and current Ro and Sesame eligibility terms.
• Next scheduled check: August 31, 2026 — Recheck the expiring 4 mg tablet price and the September 30 under-21 deadline.

Sources

1. Medi-Cal Rx Contract Drugs List, August 1, 2026
2. Changes to GLP-1 Drug Coverage for Wegovy, April 6, 2026
3. Wegovy Coverage Update — Temporary Continuation of Therapy Override, April 28, 2026
4. Reminder: Provide Medical Justification for GLP-1 Drugs, April 1, 2026
5. Archived history source: Important Update — GLP-1s for Weight Loss Are Not a Covered Benefit, October 21, 2025
6. GLP-1 Drugs — Medi-Cal Rx Members’ Frequently Asked Questions, Version 5.0
7. Changes to GLP-1 Drug Coverage — Effective January 1, 2026 member flyer
8. California State Plan Amendment 25-0029 and CMS approval
9. FDA Wegovy prescribing information
10. Medi-Cal Rx Diagnosis Crosswalk
11. Medi-Cal Rx State Fair Hearing Request Form
12. Medi-Cal Rx transition FAQ for managed care pharmacy services
13. NovoCare Wegovy savings and self-pay terms
14. NovoCare Wegovy price guide
15. NovoCare Wegovy pharmacy
16. NovoCare Wegovy list price
17. Medicare GLP-1 Bridge
18. Ro weight-loss program and insurance eligibility
19. Sesame Terms of Service
20. FDA: Compounding and the FDA — Questions and Answers
21. California member discussion used only for question framing

Related guides on The RX Index

• Medicaid GLP-1 Coverage by State — 50-state tracker
• Does Medicaid Cover Wegovy?
• How to Get Insurance to Cover a GLP-1
• Does Medicare Cover Wegovy for Weight Loss?
• Is Compounded GLP-1 Still Available?
• Find My GLP-1 Path

This page is information, not medical advice. Talk with your clinician about what is right for you. For a coverage decision, use the current Medi-Cal Rx documents and the Notice of Action for your own claim.